Last reviewed · How we verify

gatifloxacin and moxifloxacin

Donnenfeld, Eric, M.D. · Phase 2 active Small molecule

gatifloxacin and moxifloxacin is a Small molecule drug developed by Donnenfeld, Eric, M.D.. It is currently in Phase 2 development. Also known as: Zymar and Vigamox.

At a glance

Generic namegatifloxacin and moxifloxacin
Also known asZymar and Vigamox
SponsorDonnenfeld, Eric, M.D.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about gatifloxacin and moxifloxacin

What is gatifloxacin and moxifloxacin?

gatifloxacin and moxifloxacin is a Small molecule drug developed by Donnenfeld, Eric, M.D..

Who makes gatifloxacin and moxifloxacin?

gatifloxacin and moxifloxacin is developed by Donnenfeld, Eric, M.D. (see full Donnenfeld, Eric, M.D. pipeline at /company/donnenfeld-eric-m-d).

Is gatifloxacin and moxifloxacin also known as anything else?

gatifloxacin and moxifloxacin is also known as Zymar and Vigamox.

What development phase is gatifloxacin and moxifloxacin in?

gatifloxacin and moxifloxacin is in Phase 2.

Related